Evidence map›Paper›PMID 33232188›Full record

ReviewExpert opinion on drug discovery2021

The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

Shunchuan Zhang, Samuel D Rabkin

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026
    Review
  9. Oncolytic Virotherapy in Solid Tumors: A Current Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Reprogramming cancer immunity with next-generation combination therapies.Frontiers in cell and developmental biology · 2025
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shunchuan ZhangMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
Samuel D RabkinMolecular Neurosurgery Laboratory and the Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-2344-2795
Harvard University · US

Funding

Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSVR01CA160762 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RABKIN, SAMUEL DAVID · 2012 to 2023
$3.7M
NCI NIH HHS R01 CA160762
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalBiological ProductsHerpesvirus 1, HumanHumansImmunotherapyNeoplasmsOncolytic VirotherapyOncolytic VirusesAntineoplastic Agents, ImmunologicalBiological Productstalimogene laherparepvecCancerclinical trialsimmunotherapyimmunovirotherapyoncolytic virus

Identifiers

PMID33232188
PMCPMC7969427
OpenAlexW3107570319

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.